Fluoxymesterone (Halotestin) 10mg

Fluoxymesterone 10mg (Halotestin) | iRoids Pharma

Fluoxymesterone 10mg is an oral anabolic-androgenic steroid containing 10mg of Fluoxymesterone per tablet. At iRoids Pharma, we carry Fluoxymesterone 10mg as part of our oral anabolic steroid inventory for customers in markets where Fluoxymesterone is legally available.

Fluoxymesterone is the active compound in this preparation, marketed historically under the brand name Halotestin. It carries an anabolic rating of 1900 and an androgenic rating of 1600 relative to a testosterone baseline of 100, representing pharmacological activity levels that vastly exceed virtually every other oral anabolic steroid in existence. The 10mg tablet format represents the highest concentration among the historical pharmaceutical grade Halotestin tablet formats that existed during the compound’s period of clinical availability. This positions the 10mg format as the most potent per-tablet Fluoxymesterone option within both the historical pharmaceutical reference range and the iRoids Pharma catalog.

This page covers the pharmacology, concentration-specific context, and health and legal considerations relevant to anyone researching Fluoxymesterone 10mg at iRoids Pharma. It does not constitute medical advice, recommend steroid use, or provide dosage, cycle, or stacking guidance of any kind.

Product Specifications

The 10mg Format: Position Within the iRoids Pharma Range and Historical Context

The 10mg per tablet concentration of this preparation carries specific significance within both the historical pharmaceutical context and the iRoids Pharma Fluoxymesterone product range.

Historical Pharmaceutical Alignment

Pharmaceutical grade Halotestin was produced at 2mg, 5mg, and 10mg tablet formats during its period of clinical availability. The 10mg concentration consequently aligns with the maximum standard pharmaceutical clinical tablet format for Fluoxymesterone. This alignment with the historical maximum pharmaceutical tablet format is the most direct reference point the controlled clinical literature provides for Fluoxymesterone at this concentration. The research accumulated during Halotestin’s commercial availability consequently applies most directly to the 10mg format among all available Fluoxymesterone concentrations.

Position Relative to the 5mg Format at iRoids Pharma

The 10mg format delivers double the active compound per tablet compared to the 5mg format available at iRoids Pharma. Every dose-dependent pharmacological effect including androgenic activity, central nervous system stimulation, liver stress, cardiovascular lipid effects, and erythropoietic activity is consequently twice as pronounced per tablet at the 10mg concentration as at the 5mg format. For anyone researching Fluoxymesterone at iRoids Pharma who wants the maximum per-tablet potency within the historical pharmaceutical clinical concentration range, the 10mg format consequently represents that upper limit.

Dose Precision Considerations at the 10mg Format

Given Fluoxymesterone’s extreme per-milligram potency ratings of 1900 anabolic and 1600 androgenic, the dose precision implications of working with the 10mg format versus the 5mg format are directly relevant. The 10mg format provides less per-tablet dose granularity than the 5mg format. Every dose-dependent effect and every dose-dependent side effect is twice as pronounced per tablet at the 10mg format. For anyone researching this compound, this precision distinction between the 5mg and 10mg formats is consequently more pharmacologically significant than the equivalent distinction between 5mg and 10mg formats of lower-potency compounds.

What Is Fluoxymesterone

Fluoxymesterone is a synthetic anabolic-androgenic steroid derived from testosterone. Upjohn developed it in the 1950s and introduced it to the market under the Halotestin brand name. Three specific structural modifications from the testosterone base define its pharmacological profile and produce its extraordinary receptor binding characteristics.

The first modification is a methyl group at the 17-alpha carbon position. This enables oral bioavailability by protecting the compound from first-pass hepatic metabolism and is directly responsible for the hepatotoxicity profile associated with Fluoxymesterone.

The second modification is a fluorine atom at the 9-alpha position. This fluorine substitution is the structural feature primarily responsible for Fluoxymesterone’s dramatically elevated androgenic potency. Fluorination at the 9-alpha position increases resistance to metabolic inactivation and substantially amplifies androgenic receptor binding affinity compared to the non-fluorinated testosterone base.

The third modification is a hydroxyl group at the 11-beta position. This modification further alters the metabolic profile and contributes to aromatization resistance. Together with the 9-alpha fluorination, the 11-beta hydroxylation produces the combination of extreme receptor binding potency and complete aromatase resistance that defines Fluoxymesterone’s pharmacological identity.

The result of these three modifications is a compound that does not aromatize to estrogen through any pathway, does not convert through the 5-alpha reductase pathway to a more androgenic metabolite, and carries anabolic and androgenic ratings that vastly exceed the testosterone baseline from which it was structurally derived.

How Fluoxymesterone Works

Fluoxymesterone reaches systemic circulation in active form following oral administration due to the hepatic protection of 17-alpha alkylation. It then interacts with biological systems through several pharmacological mechanisms that collectively produce its characteristic clinical and performance community profile.

Androgen Receptor Binding

Fluoxymesterone binds to androgen receptors throughout the body with extraordinarily high affinity, reflected in its androgenic rating of 1600 relative to testosterone’s baseline of 100. This extreme receptor binding potency drives pronounced effects in all androgen-responsive tissues. At the 10mg concentration, this receptor binding activity is twice as pronounced per tablet as at the 5mg format, producing correspondingly more robust downstream androgenic effects per tablet across all androgen-responsive tissues.

Nitrogen Retention and Protein Synthesis

Fluoxymesterone produces strong positive nitrogen retention in skeletal muscle and accelerates protein synthesis through androgen receptor-mediated mechanisms. These anabolic effects are driven by the compound’s extraordinary receptor binding activity in muscle tissue. At the 10mg concentration, these mechanisms operate at twice the per-tablet intensity compared to the 5mg format, producing proportionally more pronounced anabolic activity per tablet.

No Aromatization

Fluoxymesterone does not convert to estrogen through the aromatase enzyme pathway. The 11-beta hydroxyl group and the 9-alpha fluorine substitution collectively prevent aromatase-mediated conversion to estradiol. Estrogenic side effects including water retention and gynecomastia are consequently not part of Fluoxymesterone’s direct pharmacological profile at any concentration, including the 10mg format.

Central Nervous System Stimulatory Effects

Fluoxymesterone produces pronounced central nervous system stimulatory effects driven by its extreme androgenic receptor binding activity. These CNS effects are more pronounced than with any other commonly discussed oral anabolic steroid and represent one of the most pharmacologically distinctive characteristics of this compound. At the 10mg concentration, these CNS stimulatory effects are twice as pronounced per tablet as at the 5mg format. Increased aggression, enhanced competitive drive, and pronounced psychological intensity are consequently more clinically significant at the 10mg concentration than at any lower Fluoxymesterone format.

Erythropoietic Effects

Fluoxymesterone stimulates erythropoietin production and red blood cell synthesis through androgen receptor-mediated mechanisms in the kidneys and bone marrow. This erythropoietic effect is one of the documented mechanisms underlying its clinical application in anemia treatment. At the 10mg concentration, this erythropoietic activity is twice as pronounced per tablet as at the 5mg format.

Clinical Background

Fluoxymesterone carries a documented clinical history across several FDA-approved indications that provides meaningful pharmacological context despite the compound’s current absence from commercial pharmaceutical markets.

Male Hypogonadism

The FDA approved Fluoxymesterone for the treatment of hypogonadism in males. This clinical application reflected its potent androgenic activity as a replacement for testosterone function in androgen-deficient men. The 10mg format aligns directly with the maximum historical pharmaceutical clinical tablet concentration, making it the format most directly characterized by the clinical research accumulated at the upper end of the hypogonadism treatment dose range.

Anemia Treatment

The FDA approved Fluoxymesterone for the treatment of certain anemias through its erythropoietic mechanism. This application documented its effects on red blood cell production and provided a clinical research context for its erythropoietic pharmacology. This application has since been superseded by more targeted agents but its documentation contributes to the pharmacological research base for the compound.

Delayed Puberty

The FDA approved Fluoxymesterone for the treatment of delayed puberty in males. This application reflected its potent androgenic activity in driving secondary sexual characteristic development and provided additional clinical context for Fluoxymesterone’s androgenic effects at the historically available pharmaceutical tablet concentrations.

Breast Cancer Palliative Treatment

Fluoxymesterone was used in some markets for palliative treatment of certain breast cancer cases. This oncological application reflected its anti-estrogenic effects through androgenic activity and provided an additional dimension to its clinical research context beyond androgen replacement applications.

Commercial Withdrawal Context

Despite multiple FDA-approved indications, Fluoxymesterone’s commercial availability in the United States declined due to its controlled substance classification and limited market demand compared to alternative treatments. Pharmaceutical grade Halotestin is no longer commercially available in the United States. The clinical research base accumulated during its period of availability consequently represents a closed historical record rather than an ongoing accumulating literature.

Fluoxymesterone 10mg Versus Related Compounds at iRoids Pharma

Versus Fluoxymesterone 5mg

Both formats contain the same active Fluoxymesterone compound with identical pharmacological mechanisms. The 10mg format delivers double the active compound per tablet compared to the 5mg format. Every dose-dependent pharmacological effect including androgenic activity, CNS stimulation, liver stress, cardiovascular lipid effects, and erythropoietic activity is consequently twice as pronounced per tablet at the 10mg concentration. The 5mg format provides greater dose precision and more conservative per-tablet pharmacological activity. The 10mg format provides the maximum per-tablet potency within the historical pharmaceutical clinical concentration range for Fluoxymesterone. Given the compound’s extreme per-milligram potency, this precision distinction between the two formats is more pharmacologically significant than equivalent milligram differences between lower-potency compounds.

Versus Methandienone 20mg

Methandienone 20mg is a 17-alpha alkylated oral anabolic steroid with significant aromatization to estrogen and anabolic and androgenic ratings of 90 to 210 and 40 to 60 respectively. Fluoxymesterone 10mg, by contrast, produces no aromatization and carries anabolic and androgenic ratings of 1900 and 1600 despite delivering only 10mg of active compound per tablet. These two compounds represent fundamentally different pharmacological profiles. Methandienone 20mg is primarily anabolic with significant estrogenic activity. Fluoxymesterone 10mg is primarily androgenic with extreme receptor binding potency, pronounced CNS stimulatory effects, and no estrogenic conversion.

Versus Mesterolone 25mg

Mesterolone 25mg is a non-17-alpha alkylated oral androgen with low hepatotoxicity, mild aromatase inhibition, SHBG binding, and minimal HPG suppression. Fluoxymesterone 10mg, by contrast, is 17-alpha alkylated with severe hepatotoxicity, no anti-estrogenic activity, and pronounced HPG suppression. Despite both being oral androgens, these two compounds represent diametrically opposite pharmacological profiles across virtually every relevant parameter. Mesterolone is an ancillary oral androgen with minimal systemic risk considerations. Fluoxymesterone 10mg is the highest per-tablet concentration of one of the most systemically potent and hepatotoxic oral androgens in existence.

Versus Oxandrolone 10mg

Oxandrolone 10mg is a non-aromatizing 17-alpha alkylated oral anabolic steroid with mild to moderate liver toxicity, active FDA approval, and a comparatively mild side effect profile. Fluoxymesterone 10mg shares the non-aromatizing characteristic and 17-alpha alkylation with Oxandrolone but differs in virtually every other pharmacological parameter. Fluoxymesterone’s anabolic rating of 1900 versus Oxandrolone’s 322 to 630, its androgenic rating of 1600 versus Oxandrolone’s 24, and its severe hepatotoxicity versus Oxandrolone’s mild to moderate profile collectively place these two compounds at opposite ends of the oral anabolic steroid spectrum despite both being non-aromatizing alkylated oral preparations at the same milligram concentration.

Versus Anastrozole 1mg

Anastrozole 1mg is a dedicated non-steroidal aromatase inhibitor with no androgenic activity, no hepatotoxicity, and a primary pharmacological role of reducing circulating estrogen through competitive aromatase inhibition. Fluoxymesterone 10mg, by contrast, is a highly hepatotoxic oral androgenic steroid with extreme androgenic receptor binding activity and no anti-estrogenic properties. These two compounds serve completely opposite pharmacological roles within the iRoids Pharma catalog. Anastrozole reduces estrogenic activity. Fluoxymesterone produces extreme androgenic activity. No meaningful pharmacological comparison between the two compounds exists beyond their shared oral administration route.

Side Effects and Health Risks

Fluoxymesterone 10mg carries one of the most serious side effect profiles of any oral anabolic steroid discussed in performance communities. The 10mg concentration represents the maximum historical pharmaceutical clinical tablet format and delivers twice the per-tablet pharmacological activity of the 5mg format. Every dose-dependent side effect consideration is consequently twice as pronounced per tablet at the 10mg concentration. These risks are well-documented in clinical literature and cannot be minimized in any responsible discussion of this compound at any concentration.

Severe Hepatotoxicity

Hepatotoxicity is the most clinically critical health risk associated with Fluoxymesterone use. The 17-alpha alkylation places severe and direct metabolic stress on hepatocytes. Fluoxymesterone’s liver toxicity is among the most severe of any commonly discussed oral anabolic steroid, reflecting both the alkylation-related hepatic stress and the compound’s extreme per-milligram potency. At the 10mg concentration, hepatic stress is twice as pronounced per tablet as at the 5mg format. Clinical documentation includes elevated liver transaminases, cholestatic effects, peliosis hepatis, and in cases of prolonged high-dose use, serious structural hepatic complications. Regular biochemical liver function monitoring is consequently an absolute essential health consideration at any Fluoxymesterone concentration, and particularly at the 10mg format.

Extreme Androgenic Effects

Fluoxymesterone’s androgenic rating of 1600 produces androgenic side effects that exceed virtually every other commonly discussed oral anabolic steroid. Severe accelerated androgenetic alopecia in genetically predisposed individuals, severe acne vulgaris, and in women profound and potentially irreversible virilization are among the most consistently documented androgenic consequences. At the 10mg concentration, these androgenic effects are twice as pronounced per tablet as at the 5mg format. They are consequently more severe than those associated with any lower Fluoxymesterone concentration and substantially more severe than those associated with any other oral anabolic steroid at comparable milligram doses.

Psychological Effects and Aggression

The CNS stimulatory effects from Fluoxymesterone’s extreme androgenic receptor binding produce psychological consequences that are among the most pronounced and consistently documented for any oral anabolic steroid. Increased aggression, irritability, mood instability, and in some documented cases more serious psychiatric disturbances are reported in clinical case reports and performance community observations. At the 10mg concentration, these effects are twice as pronounced per tablet as at the 5mg format. Consequently, psychological monitoring is more critical at the 10mg format than at any lower Fluoxymesterone concentration.

Severe Cardiovascular Effects

Fluoxymesterone produces adverse lipid profile modifications that are among the most pronounced of any oral anabolic steroid in the clinical literature. Dramatic HDL cholesterol suppression and substantial LDL cholesterol elevation carry serious long-term cardiovascular implications. The erythropoietic effects that increase red blood cell mass also raise hematocrit and blood viscosity, adding a secondary cardiovascular risk consideration. At the 10mg concentration, these cardiovascular effects are twice as pronounced per tablet as at the 5mg format and represent among the most clinically significant cardiovascular considerations associated with any oral anabolic steroid.

HPG Axis Suppression

Fluoxymesterone suppresses the hypothalamic-pituitary-gonadal axis through negative feedback mechanisms, reducing endogenous testosterone production during use. At the 10mg concentration, the degree of HPG suppression is twice as pronounced per tablet as at the 5mg format. Post-use HPG recovery may require medical intervention in some cases, particularly following extended use at the 10mg concentration.

Legal and Regulatory Status

Fluoxymesterone carries Schedule III controlled substance status in the United States under the Anabolic Steroid Control Act. Despite its historical FDA approval for specific indications, commercial availability of pharmaceutical grade Halotestin in the United States has been discontinued. Possession without a valid prescription consequently constitutes a federal offense.

In the United Kingdom, Fluoxymesterone is classified as a Class C controlled substance under the Misuse of Drugs Act. Unauthorized supply is a criminal offense.

The World Anti-Doping Agency includes Fluoxymesterone on its prohibited list across all competitive sport categories. Detection through urinary analysis is possible following use.

You are responsible for confirming the legal status of Fluoxymesterone in your specific jurisdiction before purchasing from iRoids Pharma.

Frequently Asked Questions

Is Fluoxymesterone 10mg Available at iRoids Pharma

Yes. iRoids Pharma carries Fluoxymesterone 10mg for customers in markets where Fluoxymesterone is legally available. Visit iroidspharma.com to check current availability and pricing.

What Is the Half-Life of Fluoxymesterone

Fluoxymesterone produces a half-life of approximately 9 to 10 hours. Regular daily administration is consequently required to maintain stable plasma concentrations throughout the day. This pharmacokinetic characteristic applies equally across the 5mg and 10mg formats.

How Does the 10mg Format Differ From the 5mg Format at iRoids Pharma

Both formats contain the same active Fluoxymesterone compound with identical pharmacological mechanisms. The 10mg format delivers double the active compound per tablet compared to the 5mg format. Every dose-dependent pharmacological effect and side effect is consequently twice as pronounced per tablet at the 10mg concentration. The 5mg format provides greater dose precision. The 10mg format provides the maximum per-tablet potency within the historical pharmaceutical clinical concentration range. Given Fluoxymesterone’s extreme per-milligram potency, this precision distinction is more pharmacologically significant than equivalent milligram differences between lower-potency oral anabolic steroids.

Why Does Fluoxymesterone Have Such Extreme Potency Ratings Despite Being Used at Low Milligram Doses

The anabolic and androgenic ratings reflect in vitro receptor binding affinity relative to testosterone in standardized assay conditions. They do not translate directly into proportional real-world physiological effects at equivalent doses. Fluoxymesterone’s extreme ratings reflect its powerful receptor binding characteristics and resistance to metabolic inactivation rather than a proportional amplification of all anabolic effects relative to testosterone at equivalent milligram doses.

Does Fluoxymesterone 10mg Aromatize

No. The 11-beta hydroxyl group and 9-alpha fluorine substitution collectively prevent aromatase-mediated conversion to estradiol. Estrogenic side effects are consequently not part of Fluoxymesterone’s direct pharmacological profile at any concentration including the 10mg format.

Is the 10mg Format More Appropriate Than the 5mg Format for All Users

No. The 10mg format represents the maximum per-tablet potency within the historical pharmaceutical clinical concentration range for Fluoxymesterone. It delivers twice the dose-dependent pharmacological activity per tablet compared to the 5mg format. Given the compound’s extreme per-milligram potency, the 5mg format provides greater dose management flexibility. The 10mg format is specifically relevant for anyone researching the maximum historical pharmaceutical clinical tablet concentration of this compound rather than as a universally preferred format over the 5mg option.

What Are the Most Serious Health Risks at the 10mg Concentration

Severe hepatotoxicity from 17-alpha alkylation is the most clinically critical health risk and is twice as pronounced per tablet as at the 5mg format. Extreme androgenic effects, pronounced CNS stimulatory and psychological effects, severe cardiovascular lipid dysregulation, erythropoietic blood viscosity effects, and HPG suppression complete the primary risk profile. All of these considerations are twice as pronounced per tablet at the 10mg concentration as at the 5mg format. Medical supervision and regular biochemical monitoring are consequently absolutely essential for anyone researching this compound at the 10mg concentration.

Is Fluoxymesterone 10mg Legal to Purchase

Fluoxymesterone carries Schedule III controlled substance status in the United States. Legal status varies by jurisdiction. You are consequently responsible for confirming the legal status in your jurisdiction before purchasing from iRoids Pharma.

What to Consider Before Purchasing Fluoxymesterone 10mg

Fluoxymesterone carries a documented pharmacological profile accumulated during its period of FDA-approved clinical availability and supplemented by extensive observational data from non-prescription market use. This profile characterizes it as one of the most potent and highest-risk oral anabolic steroids discussed in performance communities at any concentration. These characterizations apply with maximum force at the 10mg format, which delivers twice the per-tablet pharmacological activity of the 5mg format and represents the upper limit of the historical pharmaceutical clinical concentration range for this compound.

The 10mg format aligns directly with the maximum standard pharmaceutical clinical tablet format for Fluoxymesterone. This alignment provides the most direct clinical research reference available for this compound. The controlled literature accumulated during Halotestin’s pharmaceutical availability at doses corresponding to the 2mg to 10mg tablet formats applies most directly to the 10mg format among all available Fluoxymesterone concentrations at iRoids Pharma.

The iRoids Pharma non-prescription preparation does not carry the manufacturing oversight of pharmaceutical grade Halotestin. The clinical research base applies to the pharmacological and risk profile of the active compound regardless of the specific manufacturer. Manufacturing standards and quality verification consequently differ between pharmaceutical grade and non-prescription preparations.

Fluoxymesterone carries documented severe hepatotoxicity, extreme androgenic effects, pronounced CNS stimulatory and psychological effects, severe cardiovascular lipid dysregulation, erythropoietic blood viscosity effects, and HPG suppression that require medical supervision to manage responsibly. All of these considerations are twice as pronounced per tablet at the 10mg format compared to the 5mg format. Regular biochemical monitoring including liver function, lipid panels, hematocrit, and hormonal assessment is consequently absolutely essential for anyone researching this compound at the 10mg concentration.

For customers in markets where Fluoxymesterone is legally available, visit iroidspharma.com to check current Fluoxymesterone 10mg availability, pricing, and stock levels.